mice to SCA1 mice (Atxn1 154Q/+ ) exacerbated disease progression, whereas breeding them to Atxn1 +/À mice normalized Ataxin1 levels and largely rescued the Pum1 +/À phenotype. Thus, both increased wildtype ATAXIN1 levels and PUM1 haploinsufficiency could contribute to human neurodegeneration. These results demonstrate the importance of studying post-transcriptional regulation of disease-driving proteins to reveal factors underlying neurodegenerative disease.
In Brief
Pumilio1 is an RNA-binding protein that binds Ataxin1 mRNA and regulates its stability. Haploinsufficiency of Pumilio1 results in an increase in Ataxin1 levels, leading to progressive motor dysfunction and degeneration of Purkinje cells, features typical of spinocerebellar ataxia type 1. These data suggest that either haploinsufficiency of PUMILIO1 or duplication of ATAXIN1 could contribute to neurodegeneration in humans.
INTRODUCTION
Misfolded proteins underlie the pathogenesis of a number of neurodegenerative conditions, collectively known as proteinopathies. Alzheimer disease (AD), Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), and polyglutamine diseases such as Huntington disease all fall into this category (Ross and Poirier, 2004; Soto, 2003) . Despite the heterogeneity of their pathogenic mechanisms, in each of these diseases, the misfolded protein accumulates in neurons and exerts toxicity. Somewhat surprisingly, the brain can also be sensitive to elevated levels of wildtype (WT) protein: duplication of the amyloid precursor protein (APP) locus causes autosomal dominant early-onset AD (Rovelet- Lecrux et al., 2006; Rumble et al., 1989) , and duplications or triplications of a-synuclein (SNCA) are associated with familial PD (Chartier-Harlin et al., 2004; Ibá ñ ez et al., 2004; Singleton et al., 2003) . Along similar lines, it has been shown recently that leucine-rich repeat kinase 2 (LRRK2) mutations, the most common cause of inherited PD, increase overall protein synthesis in Drosophila, and that reduction in dLRRK levels is protective (Martin et al., 2014) .
Spinocerebellar ataxia type 1 (SCA1) is paradigmatic of the subgroup of polyglutamine (polyQ) proteinopathies caused by expansion of an unstable CAG repeat in the coding region of the relevant disease gene, in this case ATAXIN1 (ATXN1) (Orr et al., 1993) . The onset of SCA1 is usually in mid-life, when motor coordination begins to deteriorate because of cerebellar degeneration; patients eventually die of bulbar dysfunction that renders them unable to clear their airway (Zoghbi and Orr, 2009 ). There is clear evidence that the expanded polyQ tract stabilizes ATXN1 and causes it to resist being cleared by the ubiquitinproteasome pathway, in effect increasing its abundance in neurons (Cummings et al., 1999) . Notably, the severity of neurodegeneration in fly and mouse models of SCA1 correlates directly with levels of mutant ATXN1 protein (Burright et al., 1995; Fernandez-Funez et al., 2000) , and massive overexpression of even WT ATXN1 under the Purkinje-cell-specific promoter can produce a mild SCA1-like phenotype in mice (Fernandez-Funez et al., 2000) .
Although the artificiality of transgenic models limits their relevance to the human disease, these results from SCA1 transgenic mice, along with the evidence from familial AD and PD patients, led us to ask whether there were post-transcriptional modifications that might increase the levels of WT ATXN1 in a more physiologically relevant way and shed further light on the role of protein levels in neurodegeneration. The extraordinarily long 3 0 UTR, approximately 7 kb in ATXN1 mRNA, seemed to promise a rich source of key brain-enriched post-transcriptional regulatory elements. To our surprise, we found that ATXN1 is regulated directly by an RNA-binding protein (RBP), Pumilio1, and that a brain-wide increase in WT Atxn1 levels of only $50%, caused by Pum1 haploinsufficiency, is sufficient to cause marked neurodegeneration in mice.
RESULTS
The RBP PUMILIO1 Regulates ATAXIN1 Levels in Cells Two types of molecules are known to modulate protein levels by binding to the corresponding mRNA: RBPs and microRNAs (miRNAs). RBPs bind to specific sequence motifs or secondary structures in mRNAs and regulate multiple steps in RNA metabolism, such as splicing, nucleus-cytoplasm transport, and translation (Lukong et al., 2008) . On the other hand, miRNAs are small non-coding RNAs that control various developmental and physiological processes by suppressing the expression of their target genes via binding of a short (6-8 nucleotide) complementary seed region in the 3 0 UTRs of mRNAs (Bartel, 2009 ). We first scanned the $7 kb-long ATXN1 3 0 UTR for potential binding sites for miRNAs by using the TargetScan (Friedman et al., 2009) , CoMeTa (Gennarino et al., 2012) , and HOCTARdb (Gennarino et al., 2011) prediction tools. As expected, scanning identified dozens of potential miRNA-binding sites (data not shown). Because RNA folding mediates miRNA-RNA interactions by masking or exposing specific binding-site sequences, we analyzed the secondary structure of the ATXN1-3 0 UTR (Wan et al., 2014) to prioritize the best candidate ATXN1-modulating miRNAs. This revealed a complicated secondary structure that masks the binding sites for almost all of the putative miRNAs that might target the ATXN1-3 0 UTR ( Figure S1 ). For miRNAs to act on ATXN1 mRNA, they would likely require the help of RBPs to unfold such a structure.
Scan analysis of the human ATXN1-3 0 UTR revealed three putative Pumilio1 (PUM1) binding motifs (Wang et al., 2002) at positions 682, 2812, and 5275 from the beginning of the UTR ( Figure 1A ). The RBP PUM1 regulates its target genes by inducing a conformational switch in the 3 0 UTR that unmasks specific miRNA-binding sites (Kedde et al., 2010; Miles et al., 2012) . Interestingly, the motif in position 5275 ( Figure 1A , red box) is highly conserved across several species and represents the canonical PUM1-binding motif (5 0 -UGUAXAUA-3 0 ) (Galgano et al., 2008; Wang et al., 2002) . Overexpressing PUM1 in HEK293T cells reduced ATXN1 mRNA levels, whereas decreasing PUM1 by two different RNAi increased ATXN1 mRNA levels ( Figure 1B) . In vitro overexpression of PUM1 consistently decreased the luciferase activity of a reporter construct expressing the full-length ATXN1-3 0 UTR ( Figure 1C ). Mutation of each PUM1-binding motif within the ATXN1-3 0 UTR revealed that only the most conserved site, containing the canonical motif, is functional; when mutated, it abolished the effect of PUM1 overexpression on luciferase activity ( Figure 1D ).
Pum1 Is Widely Expressed in Mouse Brain and Regulates
Atxn1 Levels In Vivo To examine the endogenous expression pattern of Pum1 in mice, we performed in situ hybridization assays (ISH) and western blot on 3-week-old mouse brain sections. Pum1 was expressed in all major brain regions in WT mice, almost completely absent in the brain of null mice, and reduced in heterozygous (Pum1 +/À ) brains ( Figure S2A ). We also confirmed that Pum1 protein is widely expressed in the brain at 5 weeks of age ( Figure S2B ).
To determine whether Pum1 binds Atxn1 mRNA in vivo, we performed an RNA cross-linking and immunoprecipitation assay (RNA-Clip) on cerebra and cerebella from 5-week-old WT animals, using Pum1 knockout mice (Pum1 À/À ) as negative controls ( Figure S2C ). We found that Pum1 physically interacts with the conserved binding site of the Atxn1-3 0 UTR in WT mice ( Figure 2A) . Consistent with the finding that Pum1 negatively regulates Atxn1, Pum1 heterozygous (Pum1 +/À ) mice showed increased levels of both Atxn1 protein ( Figure 2B ) and mRNA ( Figure 2C )-approximately 30% in the cerebrum and 50% in the cerebellum-and Pum1 À/À mice showed even more pronounced increases ( Figures 2B and 2C ). These data demonstrate that Pum1 directly regulates Atxn1 levels in the mouse brain.
PUM1 Controls ATXN1 Levels by Affecting RNA Stability and not through the miRNA Machinery Several mRNA subsets contain target sites for both RBPs and miRNAs, and cooperation between these two types of post-transcriptional regulators has been described (Bhattacharyya et al., 2006; Fabian and Sonenberg, 2012; Glorian et al., 2011; Kim et al., 2009; Kundu et al., 2012) . This may be particularly relevant for PUM1, as studies have indicated extensive interaction between PUM1 and the miRNA regulatory system (Kedde et al., 2010; Galgano et al., 2008) . To determine whether PUM1 regulates ATXN1 through miRNA by inducing a conformational switch in its 3 0 UTR, we overexpressed PUM1 in HEK293T cells along with miR-101a, a miRNA known to modulate ATXN1 levels (Lee et al., 2008) . These conditions significantly reduced levels of ATXN1 protein (Figures 3A and S3A) and mRNA ( Figure S3E ), but no more than overexpressing miR-101a or PUM1 separately. In fact, overexpression of miR-101a along with PUM1 knockdown consistently decreased levels of ATXN1 protein (Figures 3B and S3B) and mRNA ( Figure S3F ) to a degree comparable to that of miR-101a overexpression alone. These results suggest that PUM1 regulates ATXN1 in a miR-101a-independent fashion but do not exclude the possibility that other miRNAs bind the ATXN1 3 0 UTR. To obviate testing the effect of PUM1 on all possible miRNAs regulating ATXN1, we knocked down the catalytic engine of the RNA-induced silencing complex (RISC), Argonaute-2 (AGO2), to globally inhibit miRNA binding and retested PUM1's ability to regulate ATXN1. We found that PUM1 overexpression in the context of AGO2 knockdown still reduced levels of both ATXN1 protein (Figures 3C and S3C) and mRNA ( Figure S3G ). Conversely, simultaneous RNAi of PUM1 and AGO2 increased levels of both ATXN1 protein (Figures 3D and S3D) and mRNA ( Figure S3H ), but no more than silencing PUM1 alone. These data establish that PUM1 modulates ATXN1 levels directly by binding its 3 0 UTR, without the assistance of the miRNA machinery.
To further explore the mechanism by which PUM1 regulates ATXN1 levels, we tested whether PUM1 influences the stability or the translation of ATXN1 mRNA. We transfected HEK293T with a luciferase reporter encoding an ATXN1-3 0 UTR harboring either the conserved WT or mutated (Mut) PUM1-binding site.
Later, we used treatment with DRB (5,6-dichloro-1-b-D-ribofuranosylbenzimidazole), a drug that inhibits RNA translation by blocking RNA polymerase II in the early elongation stage, to assess the levels of the reporter transcript. Upon the addition of DRB (time-point zero), the relative expression of reporter transcripts containing the ATXN1-3 0 UTR Mut binding site is considerably higher than that of transcripts containing the ATXN1-3 0 UTR WT binding site ( Figure 3E , top panel). This difference remains stable over time until 8 hr after DRB addition. Remarkably, the ATXN1-3 0 UTR with Mut binding site reached its half-life after 19 hr, whereas the ATXN1-3 0 UTR with WT binding site decreased linearly over time, reaching its half-life at nearly 8 hr ( Figure 3E , top panel). Given that the promoter sequences of the ATXN1-3 0 UTR constructs carrying either WT or Mut binding sites are exactly the same and that transfection of neither construct affected PUM1 protein levels, we conclude that PUM1 promotes degradation of ATXN1 by binding its 3 0 UTR (Figures 3E, bottom panel and S3I).
To investigate physiological changes in ATXN1 mRNA, we decided to knock down PUM1 in HEK293T cells and measure the half-life of endogenous ATXN1 mRNA at different time points after DRB treatment. Knockdown of PUM1 (siPUM1) was associated with a significant increase of ATXN1 mRNA from time zero and remained upregulated up to 8 hr after translation inhibition ( Figure 3F , top panel). Our calculation consistently showed that the half-life of ATXN1 mRNA was much longer (nearly 12 hr) after siPUM1 than after siScramble transfection ($4 hr) ( Figure 3F , top panel). We confirmed PUM1 downregulation by quantifying mRNA at time zero ( Figure S3J ) and protein levels at different time points (Figures 3F, bottom panel and S3K) . PUM1 thus increases ATXN1 levels by directly regulating the stability of ATXN1 mRNA.
Pum1 Mutant Mice Develop Progressive Motor Dysfunction and Neurodegeneration
Recent studies have shown that Pum1 is an essential regulator of spermatogenesis in mice and promotes differentiation of embryonic stem cells (Chen et al., 2012; Leeb et al., 2014) , but its role in the mammalian nervous system has not been investigated. We therefore characterized the brain structure and behavior of Pum1 knockout mice (Chen et al., 2012) . The Pum1 null allele tends to be transmitted with an altered Mendelian ratio ( Figure S4A ). Compared to WT and Pum1
À/À mice were significantly smaller in body length, weight, and brain weight and size (Figures 4A and S4B) . Surprisingly, the loss of one copy of Pum1 was sufficient to cause impaired performance on the accelerating rotarod assay in 5-week-old mice ( Figure 4B ): the motor deficit had progressed in severity by 12 weeks ( Figure S4C ). This motor incoordination was even more dramatic in Pum1 À/À agematched mice ( Figures 4B and S4C ), which performed equally poorly in the dowel-walking test ( Figures S4D and S4E )-as poorly, in fact, as SCA1 mice at this age in both assays (Watase et al., 2002 in an open-field chamber ( Figure S4G ) and spent less time in its center ( Figure S4H ) but traveled greater distances over 30 min in the chamber than WT ( Figure 4D ). Interestingly, Pum1 À/À mice covered a greater distance at 18 weeks than at 10 weeks of age ( Figure S4I ). Using the DigiGait assay, we found that 12-week-old Pum1 À/À mice had wider stances ( Figure S4J ), shorter stride lengths ( Figure S4K ), and greater stride frequencies ( Figure S4L ). At the same age, Pum1 +/À and Pum1 À/À mice were poor nest builders ( Figure S4M ). Pum1 deficiency thus causes progressive loss of motor coordination that appears to be cerebellar in origin.
To uncover the defects underlying the phenotype, we performed neuropathological studies. At 3 and 4 weeks of age, there was no evidence of Purkinje cell pathology in Pum1 +/À or Pum1 À/À mice ( Figures 4F and S4N ), but by 10 weeks, Pum1 haploinsufficiency had caused loss of Purkinje cells (Figures 4E and 4F) and dendritic arborization ( Figure 4G ). Both defects were more dramatic in age-matched Pum1 À/À mice ( Figures   4E-4G ). The neuronal loss is thus a result of neurodegeneration and not a developmental defect. Notably, progressive Purkinje cell degeneration and motor dysfunction are hallmarks of SCA1 in both human patients and the SCA1 knockin mouse model (Atxn1 154Q/+ ) (Watase et al., 2002) . Because the progressive defects in Pum1 mutant mice were reminiscent of those IgG as well Pum1 null mice were used as negative controls. Isolated RNA from a fraction (10%) of pre-cleared lysate was used as input. The experiment was performed in triplicate.
(B and C) Quantification of Atxn1 protein (B) and mRNA levels (C) in WT and Pum1 À/À mice in cerebrum and cerebellum (n = 8 per genotype).
Data represent mean ± SEM and normalized to Gapdh. See Experimental Procedures for more details. p values were calculated by Student's t test; *p < 0.05, **p < 0.01, ***p < 0.0001. See also Figure S2 .
observed in SCA1 mice (Watase et al., 2002) , we decided to dissect the genetic interaction between Pum1 and SCA1 mice. Figures 5A and 5B) . Notably, Figure S5C ).
Severe kyphosis (curvature of the spine) developed in Pum1 +/À ;Atxn1 154Q/+ mice 8 weeks earlier than SCA1 knockin mice (20 versus 28 weeks; Figure 5C ), confirming the accelerated disease course. In addition, Pum1 +/À ;Atxn1 154Q/+ mice had a significantly shorter lifespan than their Atxn1 154Q/+ littermates ( Figure 5D ). At 12 weeks of age, the Purkinje cell loss (Figures 5E and 5F ) and arborization defects ( Figure 5G) Figure S5A ), length, brain weight, or brain size relative to any other genotype ( Figure S6C ). Atxn1 haploinsufficiency in Pum1 mutant mice significantly mitigated the motor deficits observed in Pum1 +/À animals at 5 weeks of age ( Figure 6B ) and completely rescued the hind-paw clasping ( Figure 6C ) and kyphosis, which occurs at a later age of $25 weeks ( Figure 6D ). Interestingly, Pum1 +/À ;Atxn1 +/À mice still traveled farther than other geno- (B) Accelerating rotarod analysis. Mice were trained over 4 days with four trials (t) per day. The null mice were significantly different from WT from day 1; by day 2, the difference between WT and both Pum1 null and heterozygotes was statistically significant, as was the difference between the two mutants.
(C) Hind-paw clasping analysis in mice: a higher score indicates a more severe phenotype (see Figure S4F , bottom panel for scoring details). By 6 weeks of age, the null mice were statistically different from WT; by 8 weeks, both mutant lines were statistically significantly different from WT. types and not less than Pum1 +/À mice ( Figure S6D ). The Purkinje cell loss (Figures 6E and 6F) and arborization defects ( Figure 6G ) typical of 10-week-old Pum1 +/À mice were rescued in Pum1
+/À cerebella. This indicates that, whatever the other pathways affected by Pum1 deficiency, the cerebellar degeneration, clasping, and kyphosis are caused primarily by the influence of Pum1 on Atxn1 levels. Lastly, we analyzed whether Pum1 overexpression could decrease levels of mutant (polyglutamine-expanded) Atxn1 (154Q). We used AAV8 viral injection and found that, indeed, Atxn1 154Q/+ mice injected with Pum1/AAV8 showed a reduction of both WT and mutant Atxn1 in the cerebellum, the region most affected in SCA1, compared to controls (Atxn1 154Q/+ animals injected with YFP/AAV8; Figure S6E ).
DISCUSSION
Accumulation of mutant proteins in the brain has been known for some time to underlie the progression of neurodegenerative disorders such AD, PD, HD, ALS, and the spinocerebellar ataxias. In all these diseases, the mutant proteins form insoluble aggregates (Haass and Selkoe, 2007; Klement et al., 1998; Ross and Poirier, 2004; Zoghbi and Orr, 2000) . Considerable attention has been devoted to the question of whether inhibiting aggregate formation or promoting their dissolution would mitigate disease (Arrasate et al., 2004; Bowman et al., 2005 Bowman et al., , 2007 . The aggregates in all these proteinopathies appear late in the disease course, however, and clearly result from processes that have been taking place for decades. Here we asked how protein levels affect the brain long before aggregates form. Specifically, we sought post-transcriptional regulatory mechanisms that regulate WT ATXN1 levels independently of the polyglutamine tract in order to determine whether reducing protein levels might delay disease progression. Our studies have unexpectedly revealed two candidate genes for neurodegenerative conditions in humans: WT (but upregulated) ATAXIN1 and PUMILIO1. We began our investigation by scanning the long 3 0 UTR of ATXN1 to identify regulatory elements that could be used to modulate ATXN1 levels. We found three PUM1-binding motifs in the 3 0 UTR of ATXN1, one of which is highly conserved. We used mutagenesis and RNA-Clip to show that Pum1 regulates Atxn1 levels by binding directly to the highly conserved motif in its 3 0 UTR. Pum1 is a member of a well-characterized family of RBPs, known as the PUF family, which are involved in various physiological processes (Spassov and Jurecic, 2003; Wickens et al., 2002) . A typical feature of these proteins is the presence of an RNA-binding Pumilio homology domain (PUM-HD) that binds a highly conserved eight-nucleotide motif (Galgano et al., 2008) . PUF proteins regulate mRNA stability by several mechanisms leading to mRNA instability or translational repression (Goldstrohm et al., 2006; Suh et al., 2009) . One of the most well-studied mechanisms for PUM1 activity, however, involves the miRNA machinery: PUM1 modifies the secondary structure of the 3 0 UTR of its target mRNAs to allow regulation through specific ;Atxn1 +/À mice (n = 6 per genotype).
Staining was performed with calbindin/IP3R1 in 3D deepth-coding images. Data represent mean ± SEM. See Experimental Procedures. p values was calculated by Student's t test. ns = not significant; *p < 0.05, **p < 0.01, ***p < 0.0001. See also Figure S6 .
miRNAs Friend et al., 2012; Galgano et al., 2008; Kedde et al., 2010; Miles et al., 2012) . It was thus surprising to find that PUM1 directly regulates ATXN1 mRNA stability without harnessing the miRNA regulatory system. Equally unexpected was the discovery of a role for Pum1 in the maintenance of proper brain structure and neurological function. We found Pum1 expressed in all brain regions, but the deficits we observed in the heterozygous mice-progressive motor incoordination, hind-paw clasping, kyphosis, and Purkinje cell and dendritic degeneration-were reminiscent of the SCA1 mouse phenotype. The Pum1 null mice phenocopied the SCA1 knockin mice but developed even more severe Purkinje cell pathology, showing significant neuronal loss after only 2 months. We believe this is explained at least in part by constitutive $50% increase in WT Atxn1 in contrast with the gradual nature of the accumulation of polyglutamine-expanded proteins. Even in the SCA1 knockin mice, the mutant protein takes time to accumulate to levels that produce symptoms. In the Pum1 mutants, however, the levels of Atxn1 are elevated from the very beginning of life.
The dramatic exacerbation of disease progression in SCA1 knockin mice lacking a copy of Pum1 indicates a genetic interaction between Pumilio1 and Ataxin1, but the precocity of disease symptoms in the double mutants could conceivably arise through either of two mechanisms: the loss of one copy of Pum1 directly increasing levels of mutant Atxn1, or an additive effect ascribable to the combination of two severe mutations (loss of Pum1 and the CAG expansion in Atxn1). Our results argue for the former possibility. First, the defects observed in Pum1 mutant mice were largely corrected by reducing Atxn1 levels. Second, the Pum1 +/À ;Atxn1 +/À mice were healthier than either Pum1 +/À or Atxn1 +/À mice. Third, we found that viral overexpression of Pum1 in the mouse brain reduced both the WT and expanded [154Q] forms of the Atxn1 protein ( Figure S6E ). These three facts support the notion that the neurological deficits exhibited by the Pum1 mutant mice are caused primarily by a rise in WT Atxn1 levels, even though other Pum1 targets are undoubtedly affected as well. Without knowing the full set of Pum1 targets, we cannot rule out all other pathways, but we were able to evaluate levels of two well-studied PUM1 targets, E2F3 and p27, in Pum1 It is well established that the severity of neurodegeneration in SCA1 correlates with the levels of expanded (or even WT) ATXN1 and that decreasing ATXN1 accumulation can reverse the disease phenotypes in SCA1 models (Fernandez-Funez et al., 2000; Park et al., 2013) . It has been only relatively recently, however, that we have understood that in some neurodegenerative diseases, such as AD and PD, too much of the WT protein can produce the same phenotype as the mutant protein (Chartier-Harlin et al., 2004; Ibá ñ ez et al., 2004; Rovelet-Lecrux et al., 2006; Rumble et al., 1989; Singleton et al., 2003) . Our first study of transgenic mice overexpressing WT human ATXN1 [30Q] under the control of a Purkinje-cell-specific promoter (Pcp2-Atxn1-(CAG)30Q) failed to reveal cerebellar pathology or ataxia (Burright et al., 1995) , but our later work monitoring the mice throughout their lifespans revealed that Pcp2-Atxn1-(CAG)30Q mice develop mild Purkinje cell degeneration in later life (Fernandez-Funez et al., 2000) . This suggested that only dramatic overexpression of WT ATXN1 would be neurotoxic, but the artificiality of the transgenic model-ATXN1 cDNA was massively and postnatally expressed only in cerebellar Purkinje cells and without the 3 0 UTR-limited its relevance for human patients. Here we introduce the evidence that a moderate (30%-60%) increase in the levels of endogenous WT Atxn1, expressed in the correct temporal and spatial pattern throughout the brain and preserving all its regulatory elements, is deleterious to neuronal function.
Atxn1 is expressed throughout the brain ( Figure S2A ) from very early embryonic stages (Banfi et al., 1994 (Banfi et al., , 1996 Servadio et al., 1995) . The present study suggests that mutations in PUM1 or copy-number changes in ATXN1 could cause cerebellar neurodegeneration in humans by increasing the levels of ATXN1 throughout development. Variations in PUM1 or other factors that govern ATXN1 levels could also underlie the individual differences in SCA1 onset for the same CAG repeat length.
In conclusion, we propose that identifying molecules capable of regulating ATXN1 levels provides insight into factors that contribute to cerebellar degeneration. We further propose that studying factors that regulate the RNA stability of proteins such as APP, TAU, or a-SYN might uncover candidate genes as well as binding sites whose mutation could lead to AD or PD-two diseases for which our understanding of molecular genetic causes is still very limited. For these and the everlengthening list of neurodegenerative conditions that do not fit Mendelian categories, it may prove most fruitful to search for factors that elevate the levels of key disease-driving proteins.
EXPERIMENTAL PROCEDURES Bioinformatic Analysis
The ATXN1-3 0 UTR was downloaded from UTRdb (Grillo et al., 2010) .
The ATXN1 3 0 UTR was scanned against CoMeTa (Gennarino et al., 2012) , HOCTARdb (Gennarino et al., 2011) , and TargetScan (Friedman et al., 2009) to identify all putative miRNAs regulating ATXN1. The secondary structure of ATXN1-3 0 UTR was calculated with the Vienna RNAfold (Gruber et al., 2008) package by using default parameters in a Minimum Free energy ''MFE'' (Zuker and Stiegler, 1981) and Boltzmann ensemble ''Centroid'' (Hofacker and Stadler, 2006) . ATXN1-3 0 UTR was scanned against all known RBP motifs downloaded from the database of RBP specificities (RBPDB) (Cook et al., 2011) .
Cell Culture and Transfection
The Human embryonic kidney immortalized 293 cells (HEK293T) were grown in DMEM (Invitrogen), supplemented with 10% of heat-inactivated fetal bovine serum (FBS) and penicillin/streptomycin. All cells were incubated at 37 C in a humidified chamber supplemented with 5% CO 2 . Transfection of HEK293T cells was performed using jetPRIME Transfection Reagent (Polyplus transfection) according to the manufacturer's protocol. Cells were transfected with 50 pmol of either miRIDIAN Dharmacon microRNA Mimics (miR-101a or negative control cel-miR-67) or Ambion small interfering RNA (siAGO2, siPUM1, or scramble-siRNA control). For overexpression studies, the full cDNA of PUM1 (4,635 nt) was amplified by Platinum Taq DNA Polymerase High Fidelity (Invitrogen) and cloned into a mammalian expression vector termed pcDNA3.1(+) (Invitrogen). Cells were transfected with 0.5 mg of either pcDNA3.1(+)-PUM1 or control pcDNA3.1(+).
RNA Extraction and Quantitative Real-Time PCR HEK293T cells were seeded in 6-well plates before transfection. After 48 hr, cells were collected and processed for RNA extraction. Total RNA was obtained using the miRNeasy kit (Quiagen) according to the manufacturer's instructions. RNA extraction from mouse cerebrum or cerebellum was extracted from 75 mg of tissue. RNA was quantified using the NanoDrop 1000 (Thermo Fisher). Quality of RNA was assessed by gel electrophoresis. cDNA was synthesized using Quantitect Reverse Transcription kit (Quiagen) starting from 1 mg of DNase-treated RNA. qRT-PCR experiments were performed using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories) with PerfeCta SYBR Green FastMix, ROX (Quanta Biosciences). Real-time PCR results were analyzed using the comparative Ct method normalized against the housekeeping gene GAPDH (Vandesompele et al., 2002) . The range of expression levels was determined by calculating the standard deviation of the DCt (Pfaffl, 2001) .
Luciferase Assay
The full-length 3 0 UTR of human ATXN1 mRNA was subcloned into psiCHECK-2 vector (Promega) by XbaI and NheI restriction enzymes (Lee et al., 2008) . The partial 3 0 UTR, containing binding sites 1 (582-782), using Lipofectamine 2000 (Invitrogen). After 24 hr, luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions.
Western Blot HEK293T cells were seeded in 6-well plates before transfection. After 72 hr, cells were processed for protein extraction. For mouse tissues, the entire cerebrum and cerebellum were processed for protein extraction. Both pellet and tissues were lysed with RIPA buffer (25 mM Tris-HCL, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, and complete protease inhibitor cocktail [Roche]), then placed for 15 min on ice followed by centrifugation at 13,000 rpm at 4 C for 15 min. Proteins were quantified by Pierce BCA Protein Assay Kit (Thermo Scientific) and resolved by highresolution Bolt 4%-12% Bis-Tris Plus Gel (Life Technologies) according to the manufacturer's instruction.
RNA-CLIP
Brains from WT or Pum1 knockout mice were dissected out, and cerebella were separated from the rest of the brains. After separation, the tissue was triturated in 8 ml of ice-cold HBSS until cells were evenly dissociated with no visible chunks. The cell suspension was layered on a chilled 10 cm sterile tissue culture plate and exposed to 150 mJ/cm 2 UVC (Stratagene, model UV Stratalinker 2400) on ice. After one exposure, the cell suspension was gently swirled and exposed again to UVC at 100 mJ/cm 2 . The cell suspension was pelleted for individual immunoprecipitation (IP). Cells were lysed in lysis buffer (50 mMTris-HCl, pH 7.4, 100 mMNaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 80 U/ml RNase OUT [Invitrogen] with protease inhibitor [Roche] ). Soluble fractions were pre-cleared with protein A-sepharose beads, rabbit control IgG (Sigma), 0.05% BSA, and 0.2 mg/ml yeast tRNA (Invitrogen). Pre-cleared lysates were incubated with control IgG or Pum1 (5 mg) (Bethyl Laboratories, see Antibodies) together with protein A-sepharose beads and incubated overnight at 4 C with gentle rotation. Next day, beads were washed five times with lysis buffer. Beads were treated using 20 units of RNase-free DNase (Roche) for 15 min at room temperature, followed by 50 mg proteinase K (Roche) treatment for 30 min at 37 C. Immunoprecipated RNA was isolated using miRNeasy kit (Quiagen), and RT-PCR was performed using primers designed to amplify Atxn1 cDNA regions upstream and downstream of the predicted Pum1-binding site (see Primers). Isolated RNA from a fraction (10%) of pre-cleared lysate was used as input.
RNA Stability
Total RNA from HEK293T cells, RNA quality, cDNA synthesized, and qRT-PCR experiments were obtained as described above in RNA Extraction and Quantitative Real-Time PCR. HEK293T cells were seeded in 24-well plates before transfection for both experiments ( Figures 3E and 3F ). For Figure 3E , the partial 3 0 UTR containing the PUM1 WT or Mut binding sites 3 (5175-5375) were the same as used for the luciferase assay (see Luciferase Assay section). HEK293T cells were transfected with 30 ng of psiCHECK-2 vectors (Promega) containing ATXN1-3 0 UTR WT or Mut binding sites using Lipofectamine 2000 (Invitrogen). After 36 hr, cells were treated with 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB) at the final concentration of 20 mg/ml, and total RNA for qRT-PCR analysis was collected at different time points. Firefly data were normalized to the respective Renilla. For Figure 3F , HEK293T cells were transfected with Ambion siRNA for PUM1 (siPUM1) or Scramble (siScramble) at the final concentration of 40 nM. After 48 hr, cells were collected, and the total RNA was processed for qRT-PCR. All data were normalized to GAPDH. The housekeeping gene GAPDH was used to compare all the qRT-PCR values. All western blot experiments were performed as described in the Western Blot section. 
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